Vutrisiran Health Care Resource Utilization, Costs, Discontinuation, and Mortality: A Real-World Claims Analysis.

Nicole K Bart^1,2, Daniel P Judge³, Margarita Udall⁴, Liana Hennum⁴, Melissa Allison⁵, Avinash Dash⁶, Shradha Sanghi⁶, Rakesh Ramesh⁶, Richard Wright⁷

¹St Vincent's Health Australia and Victor Chang Cardiac Research Institute, Sydney, NSW, Australia. nicole.bart@svha.org.au.

²Victor Chang Cardiac Research Institute, Lowly Packer Building, 405 Liverpool St, Darlinghurst, NSW, 2010, Australia. nicole.bart@svha.org.au.

³Medical University of South Carolina, Charleston, SC, USA.

⁴BridgeBio Pharma, Inc., San Francisco, CA, USA.

⁵Definitive Healthcare, Framingham, MA, USA.

⁶Definitive Healthcare, Bengaluru, Karnataka, India.

⁷Cedars-Sinai Medical Center, Los Angeles, CA, USA.

PubMed DOI

Abstract

INTRODUCTION: Vutrisiran was approved by the US Food and Drug Administration for hereditary transthyretin amyloid polyneuropathy (ATTR-PN) in 2022 and for transthyretin amyloid cardiomyopathy in 2025. Real-world data on vutrisiran health care resource utilization (HCRU), costs, discontinuation, and mortality in the USA are limited. METHODS: We conducted a retrospective analysis of patients initia…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.